Two key hospitals in Somerset—Musgrove Park and Yeovil—are part of a pioneering national trial that may revolutionize sepsis treatment across the NHS. Somerset NHS Foundation Trust recently confirmed its involvement in the National Institute for Health and Care Research’s (NIHR) SHORTER study, investigating whether a five-day antibiotic course can safely replace longer treatments for sepsis.
Sepsis, commonly known as blood poisoning, triggers an excessive immune response to infection that can damage organs and tissues. While antibiotics are crucial in combating sepsis, overuse contributes to harmful side effects and the growing problem of antibiotic resistance.
Ashly Thomas, clinical research nurse at Musgrove Park Hospital, explained the trial’s approach: “We often treat patients with sepsis in critical care, but the infection’s source isn’t always clear. Our microbiology team works closely with critical care to tailor antibiotic courses individually. Typically, longer courses are prescribed, which can increase resistance and side effects.”
READ MORE: Tragic Minehead School Bus Crash Claims Life of 10-Year-Old Boy
READ MORE: Support Our Lifesaving Heroes Who Fly and Drive Across the Region
The SHORTER study divides patients into two groups. One receives the standard care, while the other undergoes a shortened five-day antibiotic regimen designed to minimize resistance. The primary measure is whether patients require additional antibiotics after hospital discharge. All data collected will assess if this shorter course is equally or more effective.
Becky Purnell, senior research nurse at Yeovil Hospital, highlighted the study’s significance: “Reducing antibiotic side effects is crucial, especially since critical care patients often receive extensive antibiotics without strong evidence on the optimal duration. By focusing on lower-risk patients, the study hopes to gather data that could influence wider treatment guidelines.”
Doctors retain final authority on patient eligibility for the study, ensuring clinical safety. Ashly added, “We collaborate closely with doctors who oversee patient care, and we fully inform patients or their next of kin about the study. Most agree to participate. We monitor patients throughout their hospital stay and follow up after discharge to assess their recovery and any subsequent antibiotic use.”
Becky emphasized patient safety throughout the trial: “Patients are examined daily, and additional antibiotics are provided if needed. We’ve made a strong start—recruiting 12 patients at Yeovil and five at Musgrove Park—with excellent support from consultants eager to advance sepsis care.”